Covid-19: Remdesivir approved for use in Australia

Photo: Reuters
Photo: Reuters
The Therapeutic Goods Administration has given provisional approval to a drug that can improve the recovery time of the most seriously ill Covid-19 patients.

The approval for remdesivir comes as Australia sees a sharp increase in coronavirus cases in Victoria, which has sparked fears the outbreak may spread across the country.

Remdesivir has been provisionally approved for use in adults and adolescent patients with severe Covid-19 symptoms who have been hospitalised.

The drug by US company Gilead Sciences is the most promising treatment so far to reduce hospitalisation time for those suffering from severe coronavirus infections, the TGA said in a statement on Friday.

The TGA says remdesivir will be available only to patients who are severely unwell, require oxygen or high level support to breathe, and are in hospital care.

However, the drug does not prevent coronavirus infection or relieve milder cases.

Australia is one of the first countries to approve the use of the drug after the European Union, Japan, and Singapore.

Add a Comment

Our journalists are your neighbours

We are the South's eyes and ears in crucial council meetings, at court hearings, on the sidelines of sporting events and on the frontline of breaking news.

As our region faces uncharted waters in the wake of a global pandemic, Otago Daily Times continues to bring you local stories that matter.

We employ local journalists and photographers to tell your stories, as other outlets cut local coverage in favour of stories told out of Auckland, Wellington and Christchurch.

You can help us continue to bring you local news you can trust by becoming a supporter.

Become a Supporter